| I5X Stock | | | EUR 0.85 0.07 8.97% |
CEO
Dr. Helen Sabzevari is President of Precigen, Inc., a wholly owned subsidiary of the Company, since November 2017. Prior to this, Dr. Sabzevari served as our Senior Vice President, Intrexon Health Therapeutics as well as Head of Research and Development of Precigen Inc. from July 2017 to November 2017. Dr. Sabzevari brings extensive expertise in research and development of immunotherapybased therapeutics as well as experience translating novel treatments from preclinical stage into the clinic. Prior to Intrexon, from 2015 to 2017, Dr. Sabzevari cofounded and served as Chief Scientific Officer of Compass Therapeutics LLC, a fullyintegrated drug discovery and development company focused on manipulating the immune system to treat human disease. From 2008 to 2014, Dr. Sabzevari served as Senior Vice President of ImmunoOncology as well as Global Head of Immunotherapy, Oncology, Global Research and Early Development at EMD Serono . During her tenure, she led the immunooncology discovery and early development translational innovation platform and brought forward numerous preclinical and clinical assets including avelumab, an approved programmed death ligand1 checkpoint inhibitor. From 1998 to 2008, Dr. Sabzevari led the Molecular Immunology Group at the Laboratory of Tumor Immunology and Biology at the US National Cancer Institute, where she was focused on design, development and delivery of novel vaccines and immunotherapies for a range of human cancers since 2020.
| Age | 57 |
| Tenure | 4 years |
| Professional Marks | Ph.D |
| Phone | 301 556 9900 |
| Web | https://www.precigen.com |
Sabzevari received her doctorate degree in cell and molecular immunology and completed her postdoctoral work at the department of immunology at the Scripps Research Institute working on various immunotherapeutic modalities in the treatment of cancer and autoimmune diseases.
Precigen Management Efficiency
The company has return on total asset
(ROA) of
(0.1219) % which means that it has lost $0.1219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.5132) %, meaning that it generated substantial loss on money invested by shareholders. Precigen's management efficiency ratios could be used to measure how well Precigen manages its routine affairs as well as how well it operates its assets and liabilities.
Precigen has accumulated 182.75
M in total debt with debt to equity ratio
(D/E) of 1.05, which is about average as compared to similar companies. Precigen has a current ratio of 5.6, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Precigen until it has trouble settling it off, either with new capital or with free cash flow. So, Precigen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Precigen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Precigen to invest in growth at high rates of return. When we think about Precigen's use of debt, we should always consider it together with cash and equity.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland. PRECIGEN INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 423 people. Precigen (I5X) is traded on Frankfurt Exchange in Germany and employs 456 people.
Management Performance
Precigen Leadership Team
Elected by the shareholders, the Precigen's board of directors comprises two types of representatives: Precigen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precigen. The board's role is to monitor Precigen's management team and ensure that shareholders' interests are well served. Precigen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precigen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Frank, Independent Director | |
| Jeffrey Kindler, Independent Director | |
| Rob Russell, VP HR | |
| Randal Kirk, Chairman of the Board, Chief Executive Officer | |
| Rick Sterling, Chief Financial Officer | |
| Cesar Alvarez, Independent Director | |
| Donald Lehr, Chief Legal Officer | |
| Vinita Gupta, Independent Director | |
| Rutul Shah, Chief Officer | |
| Jeffrey Perez, Senior Vice President — Intellectual Property Affairs | |
| Randal JD, Ex Chairman | |
| Helen MPH, CEO Pres | |
| Steven Harasym, VP Relations | |
| Fred Hassan, Independent Director | |
| James Turley, Independent Director | |
| Helen Sabzevari, President, Chief Executive Officer, President - Precigen, Inc. | |
| Harry Thomasian, Chief Officer | |
| Marie Rossi, VP Communications | |
| Dean Mitchell, Independent Director | |
| Thomas Reed, Founder, Chief Science Officer | |
| Robert Shapiro, Lead Independent Director | |
Precigen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Precigen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Precigen Stock
When determining whether Precigen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Precigen's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Precigen Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Precigen Stock: Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Precigen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in Precigen Stock please use our
How to Invest in Precigen guide.
You can also try the
Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Please note, there is a significant difference between Precigen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Precigen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precigen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.